Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Asset Writedowns and Impairment (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$69000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment fell 139.66% year-over-year to -$69000.0, compared with a TTM value of $1.1 million through Sep 2025, down 60.6%, and an annual FY2024 reading of $2.9 million, up 579.03% over the prior year.
  • Asset Writedowns and Impairment was -$69000.0 for Q3 2025 at Treace Medical Concepts, down from $81000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.0 million in Q2 2024 and bottomed at -$161000.0 in Q3 2022.
  • Average Asset Writedowns and Impairment over 5 years is $259529.4, with a median of $81000.0 recorded in 2025.
  • The sharpest move saw Asset Writedowns and Impairment crashed 150.94% in 2021, then skyrocketed 17300.0% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $200000.0 in 2021, then soared by 176.0% to $552000.0 in 2022, then plummeted by 35.69% to $355000.0 in 2023, then soared by 59.44% to $566000.0 in 2024, then plummeted by 112.19% to -$69000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for TMCI at -$69000.0 in Q3 2025, $81000.0 in Q2 2025, and $500000.0 in Q1 2025.